Citations

Showing 10 of 108152 citations.

1: Eye Tracking Analysis as a Means of Evaluating Aesthetic Result Following Toe to Thumb Transfers: A Pilot Study
Boonipat, Thanapoom , Elgendy, Tarek , Hebel, Nathan SD, Moran, Steven L. , Hebel, Nathan

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | July 27, 2021 | Volume: 9 | Issue: 7S | Pages: 12-13

10.1097/01.gox.0000769988.29307.d5 Get It

Purpose: Exceptional functional results can be obtained with toe to thumb transfers; however objective measures to evaluate the aesthetic outcome of a toe to thumb transfers remains elusive. Aesthetic evaluation of a reconstruction when performed by external raters or the patient, may be influenced by expert knowledge, emotional antecedent, or ethnic or regional bias. In this study, we were interested in determining the observers’ instantaneous, reflexive responses to the toe to thumb transfer as determined by eye-tracking analysis. Methods: 13 patients with unilateral great toe to thumb transfers were photographed using a standardized technique. None had undergone secondary procedures that changed the appearance of the transferred toe. Both hands were photographed side by side in each image. A dorsal and palmar image was taken, producing 26 photos in total. 40 observers (Average age 41.39, 14-65 yo, 18 males, 22 females), blinded to the procedure, were asked to evaluate each image for symmetry between the hands. An infrared eye-tracking camera continuously recorded their eye movements. Participants were allowed to evaluate each image for 6 seconds. Data was evaluated to determine the percent of time that was devoted to evaluating each portion of the photograph. The percent time spent in each of the lookzones was recorded. Results: i) Observers spent an average of 17.7% of their time evaluating the reconstructed thumb compared to the entire bilateral hand. This was on average 63% more time looking at the reconstructed thumb compared to the normal control thumb. (p value<0.01) ii) Observers spent 43.9% of the time looking at the reconstructed thumb compared to the entire hand of the same side. They spent 31.6% of the time looking at the normal control thumb compared to the entire hand of the same side (p value<0.01, mean 0.36 seconds on the abnormal thumb (SD 0.439)), vs. mean 0.22 seconds on normal control thumb (SD 0.305); mean 0.82 seconds on abnormal hand (SD 0.45), mean 0.69 seconds on normal contralateral hand (SD 0.423); mean 0.74 on entirely normal bilateral hand (SD 0.41)). iii) Areas of significant attention as visualized by heatmaps representing where observers focus their attention include abnormal nailbed and scar tissue at the junction between the toe and native hand skin. Conclusion: The technique described above may represent a novel and objective technique for quantifying observers’ gaze with respect to toe to thumb reconstructions and the un-altered contralateral thumb. It could be applied to other areas of hand reconstruction to help determine aesthetic outcomes. The present pilot suggests that symmetric nail size may be an area of importance for creating the sense of aesthetic success. Incorporation of this data into surgical counseling may assist the patient and medical team focus on surgical-decision making priorities.
N-Terminal Pro Brain Natriuretic Peptide, sST2, and Galectin-3 Levels in Breast Cancer Survivors
Patel, Shruti , Herrmann, Joerg , Sloan, Jeff A. , Loprinzi, Charles L. , Ruddy, Kathryn J. , Patel, Shruti R , Hazim, Antonious , Vierkant, Robert A. , Olson, Janet E. , Couch, Fergus J.

Mayo Clinic

Journal of Clinical Medicine | July 27, 2021 | Volume: 10 | Issue: 15 | Pages: 3313

10.3390/jcm10153313 | PMID 34362097 Get It

NT-proBNP, soluble ST2 (sST2), and galectin-3 are biomarkers of cardiac dysfunction that have been proposed as identifiers of patients experiencing asymptomatic cardiac dysfunction after anthracycline-based chemotherapy. This study aimed to compare the proportion of breast cancer (BC) survivors with elevated serum levels of these three putative biomarkers by prior receipt of anthracycline (yes vs. no). Five-hundred-eighty survivors of BC who had received anthracycline-based chemotherapy were matched by age and time between diagnosis and serum storage to 580 who had not. Cardiac biomarker levels were analyzed using immunoassays. Analyses were carried out using linear and logistic regression models. Anthracycline recipients had higher values of NT-proBNP than non-recipients (mean 116.0 ng/L vs. 97.0 ng/L, respectively; p < 0.001). Values for ST2 and galectin-3 did not significantly differ by receipt of anthracycline. After further adjustment for age at breast cancer diagnosis, ethnicity, and receipt of trastuzumab, associations between receipt of anthracycline and higher NT-proBNP persisted (p < 0.001), showing that NT-proBNP may be a biomarker of cardiovascular toxicity after receipt of anthracycline-based chemotherapy. Further research to assess the clinical utility of NT-proBNP testing after receipt of anthracycline is recommended. sST2 and galectin-3 do not appear to differentiate between anthracycline recipients and non-recipients amongst breast cancer survivors.
Exploring the Factors that Influence Ethical Spanish Use among Medical Students and Solutions for Improvement
Mecham, Jeffrey C. , Salazar, Marisa Martinez , Perez, Rachel , Castaneda, Uriel, Stamps, Beatriz G., Chavez, Augustine , Kling, Juliana M. , Salazar, Marisa M , Perez, Rachel M , Stamps, Beatriz Garcia, Chavez, Augustine S , Kling, Juliana M

Mayo Clinic

Teaching and Learning in Medicine | July 27, 2021 | Volume: 34 | Issue: 5 | Pages: 522-529

10.1080/10401334.2021.1949996 | PMID 34314270 Get It

Cf‐02, a novel benzamide‐linked small molecule, blunts NF‐κB activation and NLRP3 inflammasome assembly and improves acute onset of accelerated and severe lupus nephritis in mice
Yang, Shin‐Ruen , Yang, Chih‐Yu , Chen, Ann , Weng, Jui‐Chun, Wan, Chih‐Jun, Wu, Chung‐Yao, Lee, Chia‐Chung, Chan, Jia‐Feng, Hsu, Yu‐Juei , Wu, Chia‐Chao , Huang, Hsu‐Shan , Liu, Feng‐Cheng , Ka, Shuk‐Man , Chen, Ann , Huang, Hsu-Shan , Liu, Feng-Cheng , Ka, Shuk-Man , Hua, Kuo‐Feng , Weng, Jui‐Chun, Tsai, Yu‐Ling , Wu, Chung-Yao, Hsieh, Chih‐Yu , Mukhopadhyay, Debabrata

Mayo Clinic

The FASEB Journal | July 27, 2021 | Volume: 35 | Issue: 8 | Pages: No page available

10.1096/fj.202100047r | PMID 34314075 Get It

Abstract In the present study, acute onset of severe lupus nephritis was successfully treated in mice using a new, benzamide‐linked, small molecule that targets immune modulation and the NLRP3 inflammasome. Specifically, 6‐(2,4‐difluorophenyl)‐3‐(3‐(trifluoromethyl)phenyl)‐2H‐benzo[e][1,3]oxazine‐2,4(3H)‐dione (Cf‐02) (a) reduced serum levels of IgG anti‐dsDNA, IL‐1β, IL‐6, and TNF‐α, (b) inhibited activation of dendritic cells and differentially regulated T cell functions, and (c) suppressed the NF‐κB/NLRP3 inflammasome axis, targeting priming and activating signals of the inflammasome. Moreover, treatment with Cf‐02 significantly inhibited secretion of IL‐1β in lipopolysaccharide‐stimulated macrophages, but this effect was abolished by autophagy induction. These results recommend Cf‐02 as a promising drug candidate for the serious renal conditions associated with systemic lupus erythematosus. Future investigations should examine whether Cf‐02 may also be therapeutic in other types of chronic kidney disease involving NLRP3 inflammasome‐driven signaling.
Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study
Zalcberg, John , Bauer, Sebastian , Schöffski, Patrick , Serrano, César , Jones, Robin L. , Attia, Steven , D’Amato, Gina Z. , Reichardt, Peter , Somaiah, Neeta , Meade, Julie, Reichert, V., Shi, Kelvin , Sherman, Matthew L. , Ruiz‐Soto, Rodrigo , Zalcberg, John , Jones, Robin L , Serrano, César , Bauer, Sebastian , Heinrich, Michael C. , George, Suzanne , Gelderblom, Hans , Chi, Ping , Mehren, Margaret von , Blay, Jean‐Yves

Mayo Clinic

The Oncologist | July 27, 2021 | Volume: 26 | Issue: 11 | Pages: e2053-e2060

10.1002/onco.13917 | PMID 34313371 Get It

Abstract Background Ripretinib 150 mg once daily (QD) is indicated for advanced gastrointestinal stromal tumors (GISTs) as at least fourth-line therapy. In INVICTUS, ripretinib intrapatient dose escalation (IPDE) to 150 mg b.i.d. was allowed after progressive disease (PD) on 150 mg QD by blinded independent central review using modified RECIST 1.1. We report the efficacy and safety of ripretinib IPDE to 150 mg b.i.d. after PD among patients randomized to ripretinib 150 mg QD in the INVICTUS study. Materials and Methods Tumor imaging was performed every 28-day cycle for the first four cycles in the ripretinib 150 mg QD period and then every other cycle, including the 150 mg b.i.d. period. Among the ripretinib IPDE patients, progression-free survival (PFS)1 was the time from randomization until PD; PFS2 was the time from the first dose of ripretinib 150 mg b.i.d. to PD or death. Results Among 43 ripretinib IPDE patients, median PFS1 was 4.6 months (95% confidence interval [CI], 2.7–6.4) and median PFS2 was 3.7 months (95% CI, 3.1–5.3). Median overall survival was 18.4 months (95% CI, 14.5–not estimable). Ripretinib 150 mg b.i.d. (median duration of treatment 3.7 months) was well tolerated with new or worsening grade 3–4 treatment-emergent adverse events (TEAEs) of anemia in six (14%) and abdominal pain in three (7%) patients. Ripretinib 150 mg b.i.d. was discontinued because of TEAEs in seven (16%) patients. Conclusion Ripretinib 150 mg b.i.d. after PD on 150 mg QD may provide additional clinically meaningful benefit with an acceptable safety profile in patients with at least fourth-line GISTs. Implications for Practice Of the 85 patients with advanced gastrointestinal stromal tumor having received at least three prior anticancer therapies randomized to ripretinib 150 mg once daily (QD) in the phase III INVICTUS study, 43 underwent ripretinib intrapatient dose escalation (IPDE) to 150 mg b.i.d. after progressive disease (PD). Median progression-free survival was 4.6 months before and 3.7 months after ripretinib IPDE. The safety profile of ripretinib 150 mg b.i.d. was acceptable. These findings indicate ripretinib IPDE to 150 mg b.i.d. may provide additional clinical benefit in patients with PD on ripretinib 150 mg QD, for whom limited treatment options exist.
QS1: Regret After Gender Affirmation Surgery: A Systematic Review And Meta-Analysis Of Prevalence
Mascaró, Andrés, Corral, Gabriel Del, Langstein, Howard N. , Manrique, Oscar J. , Bustos, Valeria P. , Bustos, Samyd S. , Escandón, Joseph M. , Gaxiola-García, Miguel Ángel , Kushida-Contreras, Beatriz Hatsue

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | July 27, 2021 | Volume: 9 | Issue: 7S | Pages: 42-43

10.1097/01.gox.0000770160.58231.17 Get It

Purpose : There is an unknown percentage of transgender and gender non-confirming individuals who undergo gender affirmation surgeries (GAS) that experiences regret. Regret could lead to physical and mental morbidity, also questioning the appropriateness of these procedures in selected patients. The aim of this study is to evaluate the prevalence of regret in transgender individuals who underwent GAS and evaluate associated factors. Methods : A systematic review was conducted following the PRISMA guidelines. A comprehensive research strategy was performed including the following databases: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, and Daily, Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus. Random-effects meta-analysis of proportions, subgroup analysis, meta-regression, publication bias, and sensitivity analyses were performed. Results: A total of 27 studies, pooling 7,928 transgender patients that underwent any type of GAS were included in this review. The pooled prevalence of regret after GAS was 1% (95% Confidence interval [CI] <1-2%). Overall, 33% underwent transmasculine surgical procedures and 67% transfeminine procedures. The prevalence of regrets among patients undergoing transmasculine and transfeminine surgeries was <1% (IC<1-<1%) and 1% (CI<1-2%), respectively. A total of 77 patients regretted having had GAS. Of them, 28 had minor and 34 had major regrets based on Pfäfflin’s regret classification. The majority of these had “clear regret” based on Kuiper and Cohen Kettenis’ classification. Conclusion: Based on this review, there is an extremely low prevalence of regret in transgender patients after GAS. We believe this study corroborates the improvements made in regard to selection criteria for GAS. However, there is high subjectivity in the assessment of regret and lack of standardized questionnaires, which highlight the importance of developing validated questionnaires in this population.
Brain structural differences in temporal lobe and frontal lobe epilepsy patients: A voxel-based morphometry and vertex-based surface analysis
Lu, Chun‐Qiang , Gosden, Grant P, Okromelidze, Lela , Jain, Ayushi , Tatum, William O. , Quiñones‐Hinojosa, Alfredo , Middlebrooks, Erik H. , Messina, Steven A. , Middlebrooks, Erik H , Gupta, Vivek , Grewal, Sanjeet S. , Lin, Chen , Ju, Shenghong

Mayo Clinic

The Neuroradiology Journal | July 27, 2021 | Volume: 35 | Issue: 2 | Pages: 193-202

10.1177/19714009211034839 | PMID 34313179 Get It

Purpose Exploration of the effect of chronic recurrent seizures in focal epilepsy on brain volumes has produced many conflicting reports. To determine differences in brain structure in temporal lobe epilepsy (TLE) and extratemporal epilepsy (using frontal lobe epilepsy (FLE) a surrogate) further, we performed a retrospective analysis of a large cohort of patients with seizure-onset zone proven by intracranial monitoring. Methods A total of 120 TLE patients, 86 FLE patients, and 54 healthy controls were enrolled in this study. An analysis of variance of voxel-based morphometry (VBM) was used to seek morphometric brain differences among TLE patients, FLE patients, and healthy controls. Additionally, a vertex-based surface analysis was utilized to analyze the hippocampus and thalamus. Significant side-specific differences in hippocampal gray matter volume were present between the left TLE (LTLE), right TLE RTLE (RTLE), and control groups ( p<0.05, family-wise error (FWE) corrected). Results Vertex analyses revealed significant volume reduction in inferior parts of the left hippocampus in the LTLE group and lateral parts of the right hippocampus in the RTLE group compared to controls ( p<0.05, FWE corrected). Significant differences were also detected between the LTLE and control group in the bilateral medial and inferior thalamus ( p<0.05, FWE corrected). FLE patients did not exhibit focal atrophy of gray matter across the brain. Conclusion Our results highlight the variation in morphometric lateralized changes in the brain between different epilepsy onset zones, providing critical insight into the natural history of people with drug-resistant focal epilepsies.
Kawasaki Disease: A Systematic Review and Meta‐Analysis of Benefits and Harms of Common Treatments
James, Karen , Kalot, Mohamad A. , Husainat, Nedaa , Dua, Anisha B. , Byram, Kevin , Springer, Jason , Lin, Yih Chang, Turgunbaev, Marat, Villa‐Forte, Alexandra, Gorelik, Mark , Abril, Andy , Langford, Carol A. , Maz, Mehrdad , Husainat, Nedaa M , Springer, Jason M , Mustafa, Reem A , Kalot, Mohamad A , Dua, Anisha B , Chung, Sharon A.

Mayo Clinic

ACR Open Rheumatology | July 27, 2021 | Volume: 3 | Issue: 10 | Pages: 671-683

10.1002/acr2.11308 | PMID 34313406 Get It

ObjectiveKawasaki disease (KD) is a self‐limited vasculitis affecting medium‐sized vessels with a predilection for the coronary arteries. Although treatment reduces the likelihood of developing of coronary artery aneurysms, 5% of patients still develop aneurysms despite treatment, making KD the leading cause of acquired heart disease in children in the United States. Consequently, there is a great deal of interest in optimizing treatment regimens, particularly for higher‐risk patients, to decrease morbidity. The aim of this systematic review is to support the development of the American College of Rheumatology/Vasculitis Foundation for the diagnosis and management of KD, focusing on the more complex scenarios in which rheumatologists may become involved, such as high‐risk and refractory disease.MethodsEighty‐nine articles were considered for full review in this systematic literature review to address 16 Population, Intervention, Comparison, and Outcome questions related to KD. Data were abstracted in hierarchical fashion. Randomized control trials (RCTs) were considered first; if none were identified or if they contained insufficient information, comparative observational studies were then viewed, followed by single‐arm observational studies/single arms from comparative studies. Only observational studies with more than 10 subjects with vasculitis were included.ResultsEight RCTs and 28 observational studies that addressed the questions were identified. Two questions were addressed by RCTs, seven questions had at least some comparative observational studies, three questions were only addressed by single‐arm data, and four questions had no relevant studies.ConclusionThis systematic review evaluates the benefits and harms of treatments for KD beyond first‐line therapy.
Association of gastric emptying with postprandial appetite and satiety sensations in obesity
Gonzalez‐Izundegui, Daniel, Campos, Alejandro , Ricardo-Silgado, Maria Laura , Cifuentes, Lizeth , Decker, Paul A. , Tran, Linh , Burton, Duane, Dayyeh, Barham Abu, Camilleri, Michael , Eckel‐Passow, Jeanette E. , Calderon, Gerardo, Ricardo-Silgado, Maria L, Abu Dayyeh, Barham, Camilleri, M , Acosta, Andres , Campos, Alejandro , Calderon-Lopez, Gerardo , Decker, Paul A. , Vargas, Eric J. , Acosta, Andrés

Mayo Clinic

Obesity | July 27, 2021 | Volume: 29 | Issue: 9 | Pages: 1497-1507

10.1002/oby.23204 | PMID 34313001 Get It

AbstractObjectiveSatiety, defined as the duration of the sensation of fullness, is usually measured by validated visual analog scales (VAS) for appetite. Gastric function plays a key role in food intake regulation. However, the association between gastric emptying (GE) and VAS appetite is unknown.MethodsIn this cross‐sectional study, 134 participants (mean [SEM] age = 39 [0.8] years, mean [SEM] BMI = 38 [0.5] kg/m2, 67% females) completed simultaneous measurements of GE and VAS appetite. After a 320‐kcal meal, GE was measured by scintigraphy and appetite by validated 100‐mm VAS for 240 minutes. Satiation was defined as calories consumed to terminate meal and was measured by an ad libitum meal. GE, VAS, and ad libitum meal tests were measured on the same day. Percent of meal retention in the stomach, VAS area under curve (AUC0‐240 min), and overall appetite score (OAS) were calculated. Pearson correlation (ρ) determined the association of GE with VAS appetite and satiation. Appetite components were also analyzed by quartiles based on GE120 min.ResultsGE120 min was correlated with sensation of VAS hungerAUC(0‐240 min) (ρ = 0.24, p = 0.004), fullnessAUC(0‐240 min) (ρ = 0.16, p = 0.05), and OASAUC(0‐240 min) (ρ = 0.20, p = 0.02). Patients with rapid GE120 min had a mean increase in VAS hungerAUC(0‐240 min) by 32 mm/min (15.62%, p = 0.03) compared with normal/slow GE120 min.ConclusionsGE is associated with the sensations of appetite, and rapid GE is associated with increased appetite, which may contribute to weight gain.
Effects of Social Determinants of Health Care on Pediatric Thyroid Cancer Outcomes in the United States
Gruszczynski, Nelson , Meister, Kara D. , Balakrishnan, Karthik , Low, Christopher M. , Meister, Kara D , Balakrishnan, Karthik , Choby, Garret , Smith, Byron H.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | July 27, 2021 | Volume: 166 | Issue: 6 | Pages: 1045-1054

10.1177/01945998211032901 | PMID 34311618 Get It

ObjectiveTo identify social determinants of health care that are associated with poorer pediatric well‐differentiated thyroid cancer (WDTC) outcomes and increased stage at presentation.Study DesignUsing the SEER database (Surveillance, Epidemiology, and End Results), we retrospectively gathered data on pediatric WDTC across the United States between 1973 and 2015.SettingAll patients between 0 and 19 years old with a diagnosis of WDTC were included.MethodsPatient variables were analyzed for relationships to AJCC stage at presentation (American Joint Committee on Cancer), overall survival, and disease‐specific survival.ResultsAmong 3913 patients with pediatric thyroid cancer, 3185 were female (81.4%), 3366 had papillary thyroid cancer (85.3%), and 367 had follicular thyroid cancer (9.4%). Two‐ and 5‐year overall and disease‐specific survival approached 100%. However, when outcomes were analyzed by specific populations, male sex, non‐Caucasian race, poverty, and language isolation were linked to worse overall survival. Male sex and poverty were associated with poorer disease‐specific survival. Regarding overall AJCC stage at presentation, male sex and Black race were related to higher overall presenting AJCC stage. Later AJCC T stage at presentation was seen in male, Hispanic, Asian, and Black patients. There were no variables significantly related to following through with recommended surgery.ConclusionPediatric WDTC continues to carry an excellent prognosis in the United States. However, when we consider specific populations, the social determinants of health care affect survival and disease burden at presentation: male sex, poverty, language isolation, and race affected survival and/or AJCC stage at presentation in pediatric WDTC.